Patent 7635474 was granted and assigned to Regeneron Pharmaceuticals, Inc. on December, 2009 by the United States Patent and Trademark Office.
Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.